Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse, der evaluerer effektiviteten og sikkerheden af ​​oral etrasimod i behandlingen af ​​voksne deltagere med moderat til svært aktiv Crohns sygdom (CULTIVATE)

5. juni 2026 opdateret af: Pfizer

Et multicenter, randomiseret, dobbeltblindt, parallelgruppestudie for at vurdere effektiviteten og sikkerheden af ​​oral Etrasimod som induktions- og vedligeholdelsesterapi til moderat til svær aktiv Crohns sygdom

Dette er et fase 2/3-studie, der omfatter 5 delstudier designet til at evaluere effektiviteten, sikkerheden og tolerabiliteten af ​​oral etrasimod som terapi hos voksne deltagere med moderat til svær aktiv Crohns sygdom (CD), som er refraktær eller intolerant over for mindst 1 af de nuværende behandlinger for CD (dvs. kortikosteroider, immunsuppressiva eller biologiske midler). Den samlede varighed af denne undersøgelse er op til 282 uger, inklusive 28-dages screeningsperiode, behandlingsperiode på op til 274 uger (induktion, forlængelse eller vedligeholdelse og langsigtede forlængelsesperioder) og 4-ugers efter- Op-periode for sikkerhedsvurdering.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Denne undersøgelse omfatter 5 delstudier:

Delstudie A - Fase 2: Et fase 2, randomiseret, dobbeltblindt, delstudie til vurdering af sikkerheden, tolerabiliteten og effektiviteten af ​​oral etrasimod-behandling hos deltagere med moderat til svær CD, der understøtter valget af induktions- og vedligeholdelsesdosis(er) for fase 3. Delstudie A er i øjeblikket lukket for tilmelding.

Delstudie 1 - Fase 2: Et fase 2b randomiseret, dobbelt-blindt, placebokontrolleret, dosisvarierende induktionssubstudie for at evaluere etrasimod som induktionsterapi og vælge en induktions- og vedligeholdelsesdosis(er) til fortsat evaluering i fase 3. Delstudie 1 er deltager i øjeblikket.

Delstudie 2 - Induktion: Et fase 3 randomiseret, dobbeltblindt, placebokontrolleret substudie til evaluering af etrasimod som induktionsterapi.

Delstudie 3 - Vedligeholdelse: Et fase 3 randomiseret, dobbeltblindt, placebokontrolleret substudie til evaluering af etrasimod som vedligeholdelsesterapi. Deltagere fra delstudie 1 og delstudie 2 vil blive optaget i delstudie 3.

Delstudie 4 - Langtidsforlængelse: Et langsigtet forlængelsesdelstudie for deltagere, der gennemfører mindst 52 ugers behandling. Deltagere fra delstudie 3 og delstudie A er planlagt til at blive optaget i delstudie 4.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

379

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Prov. de Buenos Aires
      • Ciudadela, Prov. de Buenos Aires, Argentina, 1702
        • Instituto Medico Elsa Perez(I.M.E.P)
      • Ciudadela, Prov. de Buenos Aires, Argentina, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Local Lab)
      • Ciudadela, Prov. de Buenos Aires, Argentina, B1702GIK
        • Instituto Medico Elsa Perez (I.M.E.P.) (Pharmacy)
      • Hurlingham, Prov. de Buenos Aires, Argentina, B1686NCI
        • Estudio de La Vision (OCT, Ophthalmoscopy)
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
      • Rosario, Santa Fe Province, Argentina, S2000AUC
        • Gastroenterologia Rosario (Endoscopy)
      • Rosario, Santa Fe Province, Argentina, S2000CTC
        • Microcirugia Ocular SA (OCT, Ophthalmoscopy)
      • Rosario, Santa Fe Province, Argentina, S2000KZD
        • Consultorios extemos de Sanatorio Parque (PFT with DLCO, Pulmonar Functional Test with DLCO)
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, T4000AXL
        • Centro de Investigaciones Médicas Tucuman
    • New South Wales
      • Macquarie University, New South Wales, Australien, 2109
        • Macquarie University Hospital
      • Macquarie University, New South Wales, Australien, 2109
        • Macquarie University Hospital Pharmacy
      • Macquarie University, New South Wales, Australien, 2109
        • Macquarie Respiratory Services
      • Macquarie University, New South Wales, Australien, 2109
        • Macquarie University Hospital Clinical Trials
      • Macquarie University, New South Wales, Australien, 2109
        • MQ Health Ophthalmology
    • Queensland
      • Brisbane, Queensland, Australien, 4029
        • Royal Brisbane & Women's Hospital
      • North Mackay, Queensland, Australien, 4740
        • Coral Sea Clinical Research Institute
    • Victoria
      • Bellfield, Victoria, Australien, 3081
        • MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons
      • Epping, Victoria, Australien, 3076
        • The Northern Hospital
      • Heidelberg, Victoria, Australien, 3084
        • Austin Hospital
      • Melbourne, Victoria, Australien, 3011
        • Vision Eye Institute
      • Melbourne, Victoria, Australien, 3011
        • Footscray Hospital
      • Parkville, Victoria, Australien, 3050
        • The Royal Melbourne Hospital
      • Rosanna, Victoria, Australien, 3084
        • Heidelberg Eye Clinic
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australien, 6009
        • Lions Eye Institute Limited
      • O'Connor, Western Australia, Australien, 6163
        • The trustee for The RTS Unit Trust trading as Respiratory Testing Services
      • Ghent, Belgien, 9000
        • Universitair Ziekenhuis Gent
      • Ghent, Belgien, 9000
        • AZ Maria-Middelares
      • Leuven, Belgien, 3000
        • Universitaire Ziekenhuizen Leuven
      • Roeselare, Belgien, 8800
        • Campus Brugsesteenweg
      • Roeselare, Belgien, 8800
        • Campus Rumbeke
      • Torhout, Belgien, 8820
        • Campus Rembert Torhout
      • Yvoir, Belgien, 5530
        • Centre Hospitalier Universitaire UCL Namur - Site Godinne
      • Sofia, Bulgarien, 1527
        • UMHAT "Tsaritsa Yoanna-ISUL" EAD
      • Sofia, Bulgarien, 1431
        • "DCC Alexandrovska", EOOD
      • Sofia, Bulgarien, 1606
        • ,,University multiprofile hospital for active treatment and emergency medicine N.I. Pirogov" EAD
    • Quebec
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Pharmacy)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Radiology)
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre - Montreal General Hospital (Research Site)
      • Montreal, Quebec, Canada, H4A 3J1
        • Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
      • Montreal, Quebec, Canada, H4P 2S4
        • Eye Health MD (Ophthalmology)
    • RM
      • Santiago, RM, Chile, 8330034
        • Centro de Investigaciones Clinicas de la Universidad Catolica
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7620157
        • Clinica Universidad de Los Andes
      • Santiago, Santiago Metropolitan, Chile, 8330336
        • CeCim Biocinetic
    • Quindío Department
      • Armenia, Quindío Department, Colombia, 630004
        • IPS Fundacion Cardiomet CEQUIN
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760035
        • Centro de lnvestigaciones Clinicas S.A.S
      • Aalborg, Danmark, 9000
        • Aalborg University Hospital, Department of Medical Gastroenterology, Medicinerhuset
      • Hvidovre, Danmark, 2650
        • Hvidovre University Hospital
      • Liverpool, Det Forenede Kongerige, L7 8XP
        • Royal Liverpool University Hospital
      • London, Det Forenede Kongerige, SE1 9RT
        • Guys & St Thomas Hospital
      • Norwich, Det Forenede Kongerige, NR4 7UQ
        • Quadram Institute Clinical Research Facility
      • Alexandria, Egypten, 21131
        • Alexandria Clinical Research Center , Faculty of Medicine , Alexandria University
      • Cairo, Egypten
        • National Hepatology and Tropical Medicine Research Institute
      • Cairo, Egypten, 11556
        • Ain Shams University Hospital
      • Cairo, Egypten
        • Air Force Specialized Hospital(AFSH)
      • Cairo, Egypten
        • Cairo University , Kasr Al Aini Hospital
      • Dakahlia, Egypten
        • Egyptian Liver Research Institute and Hospital ( ELRIAH)
      • Giza, Egypten
        • Theodor Bilharz Research Institute Research Ethics Committee
      • Menofeya, Egypten, 32511
        • National Liver Institute
    • Alabama
      • Dothan, Alabama, Forenede Stater, 36301
        • Digestive Health Specialists
      • Dothan, Alabama, Forenede Stater, 36301
        • Dothan Eyecare-Dr. Brent McKinley (OCT Location)
      • Dothan, Alabama, Forenede Stater, 36301
        • Center for Digestive Health (Endoscopy Location)
      • Dothan, Alabama, Forenede Stater, 36301
        • Pulmonary Associates (PFT Location)
      • Dothan, Alabama, Forenede Stater, 36305
        • Flowers Hospital (Imaging Location)
      • Mobile, Alabama, Forenede Stater, 36608
        • Digestive Health Specialists (Satellite Clinic Location)
      • Mobile, Alabama, Forenede Stater, 36608
        • Premier Medical Group East (Opthalmology & Optometry Facility)
      • Mobile, Alabama, Forenede Stater, 36608
        • Pulmonary Associates (Chest X-Ray & PFT Facility)
      • Mobile, Alabama, Forenede Stater, 36608
        • Surgicare of Mobile (Endoscopy & Biopsy Facility)
    • Arizona
      • Peoria, Arizona, Forenede Stater, 85381
        • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
      • Peoria, Arizona, Forenede Stater, 85381
        • SimonMed Imaging (Imaging)
      • Sun City, Arizona, Forenede Stater, 85351
        • Sun City Endoscopy Center (Endoscopy)
    • California
      • Apple Valley, California, Forenede Stater, 92307
        • Om Research LLC
      • Apple Valley, California, Forenede Stater, 92307
        • Victor Valley Advanced Imaging
      • La Jolla, California, Forenede Stater, 92037
        • UCSD lnvestigational Drug Service Pharmacy
      • La Jolla, California, Forenede Stater, 92093
        • Shiley Eye Institute (OCT)
      • La Jolla, California, Forenede Stater, 92037
        • Koman Family Outpatient Pavilion (ENDO)
      • La Jolla, California, Forenede Stater, 92037
        • Perlman Medical Offices
      • La Jolla, California, Forenede Stater, 92037
        • UCSD Clinical and Translational Research Institute
      • La Jolla, California, Forenede Stater, 92037
        • UCSD Health System (Endo/PFT/DLCO)
      • Lancaster, California, Forenede Stater, 93534
        • Om Research LLC
      • Lancaster, California, Forenede Stater, 93534
        • A V Pediatrics, Allergy and Family Medicine - PFT
      • Lancaster, California, Forenede Stater, 93534
        • Advanced Endoscopy and Pain Center - Colonoscopy
      • Lancaster, California, Forenede Stater, 93534
        • Advanced Imaging Center - Chest X-Ray
      • Lancaster, California, Forenede Stater, 93534
        • Antelope Valley Eye Care - Ophthalmologist
      • Lancaster, California, Forenede Stater, 93534
        • AV Pediatrics Allergy and Family Medicine
      • Lancaster, California, Forenede Stater, 93534
        • Jatinder S. Pruthi, MD FACG CPI
      • Murrieta, California, Forenede Stater, 92563
        • United Medical Doctors
      • Victorville, California, Forenede Stater, 92392
        • Retina Consultants of Southern California
      • Victorville, California, Forenede Stater, 92395
        • Physicians Surgery Center
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80907
        • Peak Gastroenterology Associates
      • Colorado Springs, Colorado, Forenede Stater, 80903
        • Front Range Endoscopy Center
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Colorado Springs Pulmonary Consultants, PC
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • The Wright Eye Center (OCT Facility)
      • Colorado Springs, Colorado, Forenede Stater, 80919
        • Colorado Springs Imaging (Ultrasound and MRE Location)
    • Florida
      • Boca Raton, Florida, Forenede Stater, 33487
        • Xera Med Research
      • Boynton Beach, Florida, Forenede Stater, 33472
        • RecioMed Clinical Research Network, Inc
      • Brandon, Florida, Forenede Stater, 33511
        • Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
      • Clearwater, Florida, Forenede Stater, 33756
        • West Coast Endoscopy Center (Endoscopy Procedures)
      • Clearwater, Florida, Forenede Stater, 33756
        • Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
      • Clearwater, Florida, Forenede Stater, 33761
        • Northwood Vision (Optical Coherence Tomography)
      • Clearwater, Florida, Forenede Stater, 33761
        • Safety Harbor Surgery (Endoscopy Procedures)
      • Clearwater, Florida, Forenede Stater, 33762
        • Gastro Florida (Regulatory Administrative Duties)
      • Coral Gables, Florida, Forenede Stater, 33134
        • Beraja Medical Institute (OCT)
      • Hialeah, Florida, Forenede Stater, 33012
        • Advanced Eye Center
      • Jacksonville, Florida, Forenede Stater, 32256
        • Encore Borland-Groover Clinical Research
      • Jacksonville, Florida, Forenede Stater, 32207
        • UF Health Imaging Center-Emerson (chest x-rays)
      • Jacksonville, Florida, Forenede Stater, 32207
        • UF Health Laboratory Emerson (blood draws)
      • Jacksonville, Florida, Forenede Stater, 32209
        • UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
      • Jacksonville, Florida, Forenede Stater, 32209
        • UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
      • Jacksonville, Florida, Forenede Stater, 32209
        • UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
      • Jacksonville, Florida, Forenede Stater, 32209
        • UF Health Radiology-Jacksonville (chest x-rays)
      • Jacksonville, Florida, Forenede Stater, 32216
        • Cisca Pulmonary & Critical Care (PFT Facility)
      • Jacksonville, Florida, Forenede Stater, 32216
        • Nicolitz Eye Consultants (OCT Facility)
      • Jacksonville, Florida, Forenede Stater, 32256
        • Borland-Groover Clinic (Endoscopy Facility)
      • Jupiter, Florida, Forenede Stater, 33458
        • Jupiter Outpatient Surgery Center
      • Kissimmee, Florida, Forenede Stater, 34741
        • IHS Health, LLC
      • Largo, Florida, Forenede Stater, 33773
        • Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
      • Miami, Florida, Forenede Stater, 33133
        • Infinite Clinical Research
      • Miami, Florida, Forenede Stater, 33156
        • Research Associates of South Florida
      • Miami, Florida, Forenede Stater, 33176
        • Anchor Medical Research, LLC
      • Miami, Florida, Forenede Stater, 33134
        • The Endoscopy Center (Endoscopy Procedure)
      • Miami, Florida, Forenede Stater, 33173
        • Juan Barrio, MD (PFT when needed)
      • Miami, Florida, Forenede Stater, 33133
        • Pulmonology Physicians of South Florida
      • Miami, Florida, Forenede Stater, 33133
        • Reina Eye Care P.A.
      • Miami, Florida, Forenede Stater, 33155
        • La Salud Research Clinic Inc.
      • Miami, Florida, Forenede Stater, 33156
        • South Florida Center for Endoscopy and Digestive Disease, LLC
      • Naples, Florida, Forenede Stater, 34102
        • Gastroenterology Group of Naples
      • Naples, Florida, Forenede Stater, 34102
        • Gulfshore Endoscopy Center
      • Naples, Florida, Forenede Stater, 34103
        • Retina Consultants of Southwest Florida OCT only
      • Naples, Florida, Forenede Stater, 34109
        • Lisette Delgado Sanchez, MD PFT only
      • Orlando, Florida, Forenede Stater, 32825
        • Pediatric & Adult Research Center
      • Palmetto Bay, Florida, Forenede Stater, 33157
        • IMIC Inc.
      • Palmetto Bay, Florida, Forenede Stater, 33157
        • IMIC Inc
      • Port Orange, Florida, Forenede Stater, 32127
        • Advanced Medical Research Center
      • Seminole, Florida, Forenede Stater, 33777
        • Bardmoor GastroEnterology
      • South Miami, Florida, Forenede Stater, 33143
        • Larkin Community Hospital (Endoscopy Procedure)
      • St. Petersburg, Florida, Forenede Stater, 33705
        • St. Petersburg Endoscopy Center (Endoscopy Procedures)
      • St. Petersburg, Florida, Forenede Stater, 33707
        • Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
      • St. Petersburg, Florida, Forenede Stater, 33709
        • Bay Area Endoscopy and Surgery Center (Endoscopy only)
      • St. Petersburg, Florida, Forenede Stater, 33709
        • Theia Clinical Research, LLC
      • St. Petersburg, Florida, Forenede Stater, 33710
        • Advanced Research Institute Inc.(IP and PFT)
      • Sun City Center, Florida, Forenede Stater, 33573
        • Absolute Surgical Specialist - Craig Amshel, MD
      • Tampa, Florida, Forenede Stater, 33612
        • USF Health Morsani Center for Advanced Healthcare
      • Tampa, Florida, Forenede Stater, 33606
        • USF Health South Tampa Center for Advanced Healthcare
      • Tampa, Florida, Forenede Stater, 33609
        • GCP Clinical Research,LLC
      • Tampa, Florida, Forenede Stater, 33609
        • South Tampa Surgery Center
      • Tampa, Florida, Forenede Stater, 33609
        • Newsome Eye Specialist (OCT Procedures Only)
      • Tampa, Florida, Forenede Stater, 33606
        • Lab - Processing/ Storage
      • Tampa, Florida, Forenede Stater, 33609
        • LoCicero Medical Group
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30342
        • Atlanta Gastroenterology Associates
      • Atlanta, Georgia, Forenede Stater, 30309
        • Digestive Healthcare of Georgia
      • Atlanta, Georgia, Forenede Stater, 30324
        • Ross Eyecare - Opthalmoscopy and OCT
      • Atlanta, Georgia, Forenede Stater, 30342
        • Atlanta Gastroenterology Associates (endoscopy only)
      • Atlanta, Georgia, Forenede Stater, 30342
        • Atlanta Gastroenterology Associates(IP only)
      • Atlanta, Georgia, Forenede Stater, 30309
        • Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
    • Illinois
      • Arlington Heights, Illinois, Forenede Stater, 60005
        • GI Alliance
      • Arlington Heights, Illinois, Forenede Stater, 60005
        • Northwest Endoscopy Center (Endoscopy)
      • Gurnee, Illinois, Forenede Stater, 60031
        • GI Alliance (PFT)
      • Gurnee, Illinois, Forenede Stater, 60031
        • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
      • Gurnee, Illinois, Forenede Stater, 60031
        • Medical Eye Services LTD (Ophthalmoscopy with OCT)
      • Lake Bluff, Illinois, Forenede Stater, 60044
        • North Shore Endoscopy Center (Endoscopy)
      • Libertyville, Illinois, Forenede Stater, 60048
        • Libertyville Imaging Center (Diagnostic Imaging)
      • Morton Grove, Illinois, Forenede Stater, 60053
        • 3T Imaging of Morton Grove (Diagnostic Imaging)
    • Maryland
      • Columbia, Maryland, Forenede Stater, 21045
        • Cascades Endoscopy Center
      • Columbia, Maryland, Forenede Stater, 21044
        • Charter Radiology
      • Columbia, Maryland, Forenede Stater, 21045
        • Gastro Center of Maryland, LLC
      • Hanover, Maryland, Forenede Stater, 21076
        • Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
      • Laurel, Maryland, Forenede Stater, 20707
        • Lung Center (Pulmonary Function Test only)
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39216
        • Southern Therapy and Advanced Research, LLC
      • Jackson, Mississippi, Forenede Stater, 39216
        • A Terrell Williams, MD, PLLC (OCT)
      • Jackson, Mississippi, Forenede Stater, 39216
        • Jackson Pulmonary Associates (PFT)
      • Jackson, Mississippi, Forenede Stater, 39216
        • St. Dominic Ambulatory Surgery Center (colonoscopy, Endoscopy)
    • Missouri
      • Creve Coeur, Missouri, Forenede Stater, 63141
        • Barnes-Jewish West County Hospital (Additional Endoscopy Location)
      • St Louis, Missouri, Forenede Stater, 63110
        • Barnes-Jewish Hospital
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Forenede Stater, 63108
        • Washington University School of Medicine
    • New Jersey
      • Freehold, New Jersey, Forenede Stater, 07728
        • Allied Health Clinical Research Organization, LLC
      • Freehold, New Jersey, Forenede Stater, 07728
        • Freehold Endoscopy Associates, LLC d/b/a Endoscopy Center of Monmouth County
      • Freehold, New Jersey, Forenede Stater, 07728
        • Freehold Ophthalmology
      • Freehold, New Jersey, Forenede Stater, 07728
        • Monmouth Ocean Pulmonary Medicine
      • Freehold, New Jersey, Forenede Stater, 07728
        • Princeton Radiology
    • New York
      • New York, New York, Forenede Stater, 10016
        • NYU Langone Health
      • New York, New York, Forenede Stater, 10016
        • NYU Langone Inflammatory Bowel Disease Center
      • New York, New York, Forenede Stater, 10016
        • NYU Langone Eye Center (Ophthalmology)
      • New York, New York, Forenede Stater, 10016
        • NYU Langone Health - Ambulatory Care Center
      • New York, New York, Forenede Stater, 10016
        • NYU Langone Health, Investigational Pharmacy, Perlmutter Cancer Center
      • New York, New York, Forenede Stater, 10016
        • NYU Pulmonary and Critical Care Associates (Pulmonary)
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28215
        • Carolinas Research Center
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Queen City Gastroenterology and Hepatology (Endoscopy)
      • Charlotte, North Carolina, Forenede Stater, 28211
        • Greenman Eye Associates (OCT)
      • Charlotte, North Carolina, Forenede Stater, 28273
        • Cornerstone Medical (Imaging & PFT)
    • Ohio
      • Chardon, Ohio, Forenede Stater, 44024
        • Geauga Sleep Center(PFT only)
      • Cincinnati, Ohio, Forenede Stater, 45219
        • UC Health Physicians Office
      • Cincinnati, Ohio, Forenede Stater, 45229
        • UC Health (Pulmonary Function Testing)
      • Cincinnati, Ohio, Forenede Stater, 45219
        • UC Health Hoxworth (OCT only)
      • Cincinnati, Ohio, Forenede Stater, 45219
        • University of Cincinnati Medical Center (PFT and Endoscopy location)
      • Mentor, Ohio, Forenede Stater, 44060
        • Great Lakes Gastroenterology Research, LLC
      • Mentor, Ohio, Forenede Stater, 44060
        • The Endoscopy Center of Lake County
      • Mentor, Ohio, Forenede Stater, 44060
        • Ophthalmic Physicians Incorporated (OCT Only)
      • Mentor, Ohio, Forenede Stater, 44060
        • Vitreo Retinal Consultants(OCT only)
      • Willoughby, Ohio, Forenede Stater, 44094
        • Lake Pulmonary Associates (PFT only)
      • Willoughby Hills, Ohio, Forenede Stater, 44094
        • Retina Specialists of Ohio(OCT only)
    • Oklahoma
      • Norman, Oklahoma, Forenede Stater, 73071
        • Norman Endoscopy Center
      • Norman, Oklahoma, Forenede Stater, 73071
        • Physicians and Surgeons X-Ray
      • Oklahoma City, Oklahoma, Forenede Stater, 73118
        • Central Sooner Research
      • Oklahoma City, Oklahoma, Forenede Stater, 73102
        • Hightower Clinical
      • Oklahoma City, Oklahoma, Forenede Stater, 73102
        • Saint Anthony Endoscopy Center
      • Oklahoma City, Oklahoma, Forenede Stater, 73102
        • SSM Health, Saint Anthony Hospital
      • Oklahoma City, Oklahoma, Forenede Stater, 73120
        • Johnston Opthalmology
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State Milton S. Hershey Medical Center
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Central Texas Clinical Research
      • Cypress, Texas, Forenede Stater, 77429
        • Houston Pulmonary Sleep and Allergy Associates (PFT)
      • Houston, Texas, Forenede Stater, 77030
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, Forenede Stater, 77030
        • Baylor St. Luke's Medical Center
      • Houston, Texas, Forenede Stater, 77047
        • Pearland Surgery Center
      • Houston, Texas, Forenede Stater, 77030
        • Alkek Eye Center Jamail Specialty Care Center (OCT)
      • Houston, Texas, Forenede Stater, 77024
        • Houston Eye Associates (For Eye Examination)
      • Houston, Texas, Forenede Stater, 77030
        • Baylor College of Medicine - Baylor St. Luke's Medical Center
      • Houston, Texas, Forenede Stater, 77030
        • Baylor St. Luke's Medical Center - McNair Campus (pharmacy)
      • Houston, Texas, Forenede Stater, 77030
        • Baylor St. Luke's Medical Center - McNair Campus
      • Houston, Texas, Forenede Stater, 77030
        • Baylor St. Luke's Medical Center Endoscopy - McNair Campus
      • Houston, Texas, Forenede Stater, 77030
        • Mann Eye Institute
      • Houston, Texas, Forenede Stater, 77030
        • Memorial Hermann Hospital- TMC Investigational Drugs Services Pharmacy (Drug Storage)
      • Houston, Texas, Forenede Stater, 77034
        • Bay Area Endoscopy Center, LLC
      • Houston, Texas, Forenede Stater, 77055
        • Memorial Endoscopy Center (For Colonoscopy)
      • Houston, Texas, Forenede Stater, 77065
        • Eye Specialists of Texas
      • Houston, Texas, Forenede Stater, 77065
        • Northside Gastroenterology Associates PA
      • Houston, Texas, Forenede Stater, 77079
        • Memorial Pulmonology(For PFT)
      • Houston, Texas, Forenede Stater, 77204
        • Digestive Health Associates
      • Houston, Texas, Forenede Stater, 77204
        • Memorial Hermann Memorial City Digestive Health Center (For Colonoscopy)
      • Pearland, Texas, Forenede Stater, 77584
        • LinQ Research, LLC
      • Tyler, Texas, Forenede Stater, 75701
        • Tyler Research Institute, LLC
      • Tyler, Texas, Forenede Stater, 75701
        • UT Health East Texas Physicians (pulmonary functions only)
      • Tyler, Texas, Forenede Stater, 75701
        • Christus Trinity Mother Frances Endoscopy Center (endoscopies only)
      • Tyler, Texas, Forenede Stater, 75701
        • Heaton Eye Associates (OCT only)
      • Victoria, Texas, Forenede Stater, 77904
        • Victoria Gastroenterology
      • Victoria, Texas, Forenede Stater, 77904
        • Citizens Healthplex (for PFT only)
      • Victoria, Texas, Forenede Stater, 77904
        • Surgery Center (For endoscopy only)
      • Victoria, Texas, Forenede Stater, 77904
        • Victoria Eye Center (For OCT only)
      • Webster, Texas, Forenede Stater, 77598
        • GI Alliance Webster
    • Virginia
      • Forest, Virginia, Forenede Stater, 24551
        • Harman Eye Center (OCT only)
      • Lynchburg, Virginia, Forenede Stater, 24502
        • Blue Ridge Medical Research
      • Lynchburg, Virginia, Forenede Stater, 24501
        • Lynchburg Pulmonary Associates, Inc. (PFT only)
    • Washington
      • Issaquah, Washington, Forenede Stater, 98029
        • Swedish Endoscopy Center - Issaquah
      • Seattle, Washington, Forenede Stater, 98122
        • Swedish Medical Center
      • Seattle, Washington, Forenede Stater, 98104
        • Swedish Gastroenterology
      • Seattle, Washington, Forenede Stater, 98104
        • Pacific Northwest Retina
      • Seattle, Washington, Forenede Stater, 98104
        • Richard Bensinger, MD
      • Seattle, Washington, Forenede Stater, 98122
        • First Hill Endoscopy Center
      • Seattle, Washington, Forenede Stater, 98122
        • Pulmonary Function Lab
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Froedtert Memorial Lutheran Hospital
      • Amiens, Frankrig, 80054
        • CHU Amiens Picardie
      • Clermont-Ferrand, Frankrig, 63000
        • Chu Gabriel Montpied
      • Clermont-Ferrand, Frankrig, 63000
        • CHU De Clermont Ferrand - Hopital Estaing
      • Grenoble, Frankrig, 38043
        • CHU Grenoble Alpes - Hopital Michallon
      • Grenoble, Frankrig, 38043
        • Endoscopy: CHU Grenoble Alpes- Hopital Michallon
      • La Roche-sur-Yon, Frankrig, 85925
        • CHD Vendee, Unite de Recherche Clinique
      • Lille, Frankrig, 59037
        • CHU de Lille - Hôpital Claude Huriez
      • Lille, Frankrig, 59037
        • Optical Coherence Tomography and Ophthalmology CHU de Lille Hopital Roger Salengro
      • Lille, Frankrig, 59037
        • Pulmonary Function Test CHU Lille, Institut Coeur Poumon
      • Montpellier, Frankrig, 34295
        • CHU Saint-Eloi
      • Montpellier, Frankrig, 34295
        • Hopital Saint-Eloi - Pole Digestif - Hgea Recherche Clinique - Rdc
      • Nice, Frankrig, 06202
        • CHU de Nice, Hopital 1'Archet 2
      • Reims, Frankrig, 51100
        • Hopital Maison Blanche, CHU DE REIMS
      • Reims, Frankrig, 51092
        • Hopital Robert Debre
      • Reims, Frankrig, 51100
        • Hopital Robert Debre CHU DE REIMS
      • Saint-Etienne, Frankrig, 42055
        • CHU Saint Etienne - Hôpital Nord
      • Saint-Priest-en-Jarez, Frankrig, 42270
        • Optical Coherence Tomography and Ophthalmology
      • Saint-Priest-en-Jarez, Frankrig, 42270
        • Pulmonary Function Test
      • Toulouse, Frankrig, 31059
        • Hopital Rangueil
      • Toulouse, Frankrig, 31300
        • Hopital Purpan PPR pole cephalique
      • Vandœuvre-lès-Nancy, Frankrig, 54511
        • CHRU Nancy Brabois
      • Tbilisi, Georgien, 0160
        • LTD Aversi Clinic
      • Tbilisi, Georgien, 0159
        • LTD Institute of Clinical Cardiology
      • Tbilisi, Georgien, 0160
        • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
      • Tbilisi, Georgien, 0160
        • LTD Academician Nikoloz Kipshidze Central University Clinic
      • Tbilisi, Georgien, 0172
        • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, LTD
      • Tbilisi, Georgien, 0179
        • LTD Medical Center "CITO"
      • Alexandroupoli, Grækenland, 681 00
        • University General Hospital of Alexandroupoli
      • Athens, Grækenland, 10676
        • General Hospital of Athens "Evangelismos"
    • Crete
      • Heraklion, Crete, Grækenland, 71500
        • Univerisity General Hospital of Heraklion
      • Amsterdam, Holland, 1105 AZ
        • Academic Medical Centre
      • Utrecht, Holland, 3584 CX
        • UMC Utrecht
      • Homyel, Hviderusland, 246029
        • Institution "Gomel Regional Clinical Hospital"
      • Minsk, Hviderusland, 220096
        • Health care Institution "10th City Clinical Hospital"
      • Mogilev, Hviderusland, 212018
        • Health Care Institution "Mogilev Hospital #1"
      • Vitebsk, Hviderusland, 210037
        • Health Care Institution "Vitebsk Regional Clinical Hospital"
      • Vitebsk, Hviderusland, 210604
        • Healthcare Institution "Vitebsk Regional Clinical Specialized Center"
      • Kochi, Indien, 682027
        • Aster Medcity, Aster DM Healthcare Ltd.
    • Gujarat
      • Surat, Gujarat, Indien, 395002
        • Surat Institute of Digestive Sciences
    • Haryana
      • Gurugram, Haryana, Indien, 122002
        • Fortis Memorial Research Institute
    • Maharashtra
      • Nagpur, Maharashtra, Indien, 440010
        • Midas Multispeciality Hospital Pvt. Ltd
    • Rajasthan
      • Jaipur, Rajasthan, Indien, 302001
        • S. R. Kalla Memorial Gastro & General Hospital
      • Afula, Israel, 1834111
        • Haemek Medical Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Ramat Gan, Israel, 5262000
        • Chaim Sheba Medical Center
      • Tel Aviv, Israel, 6423906
        • Tel Aviv Sourasky Medical Center
      • Catania, Italien, 829-95126
        • Azienda Ospedaliera Ospedale Cannizzaro
      • Catanzaro, Italien, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente Campus Universitario "Salvatore Venuta"
      • Catanzaro, Italien, 88100
        • A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente
      • Catanzaro, Italien, 88100
        • CAMPUS GERMANETO Magazzino farmaci e dispositivi medici, uffici
      • Pavia, Italien, 27100
        • Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
      • Rome, Italien, 00189
        • PFT address: Azienda Ospedaliero-Universitaria Sant' Andrea UOC Pneumologia
      • Verona, Italien, 37024
        • IRCCS Ospedale Sacro Cuore Don Calabria
      • Verona, Italien, 37134
        • OCT/PFT/Endoscopy address: CRC - Cenro Ricerche Cliniche di Verona
    • Foggia
      • San Giovanni Rotondo, Foggia, Italien, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
      • San Giovanni Rotondo, Foggia, Italien, 71013
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Casa Sollievo della Sofferenza
    • MI
      • Milan, MI, Italien, 20132
        • Ospedale San Raffaele
    • Milan
      • Garbagnate Milanese, Milan, Italien, 20024
        • ASST Rhodense - Pneumology Unit
      • Milan, Milan, Italien, 20017 Rho
        • ASST Rhodense, U.O.C. Gastroenterologia ed Endoscopia Digestiva
      • Rho, Milan, Italien, 20017
        • ASST Rhodense - Ophthalmology Unit
    • Milano
      • Rozzano, Milano, Italien, 20089
        • Irccs Humanitas Research Hospital
    • Verona
      • Negrar, Verona, Italien, 37024
        • OCT/ PFT/ Endoscopy address: IRCCS Ospedale Sacro Cuore Don Calabria
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-0871
        • Kokikai Tsujinaka Hospital Kashiwanoha
      • Nagareyama-shi, Chiba, Japan, 270-0116
        • Ishii Eye Clinic
    • Fukuoka
      • Kitakyushu-shi, Fukuoka, Japan, 807-8555
        • Hospital of the University of Occupational and Environmental Health
      • Kitakyusyu-shi, Fukuoka, Japan, 802-8561
        • Kitakyushu Municipal Medical Center
    • Ibaraki
      • Toride-shi, Ibaraki, Japan, 302-0014
        • Matsumoto Eye Clinic
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Japan, 892-0846
        • Sameshima Hospital
      • Kagoshima, Kagoshima-ken, Japan, 892-0824
        • Jiaikai Idzuro Imamura Hospital
      • Kagoshima, Kagoshima-ken, Japan, 890-0062
        • Kagoshima Kouseiren Hospital
      • Kagoshima, Kagoshima-ken, Japan, 892-0825
        • Sameshima Eye Clinic
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 861-8520
        • Japanese Red Cross Kumamoto Hospital
    • Saga-ken
      • Saga, Saga-ken, Japan, 849-8501
        • Saga University Hospital
    • Tokyo
      • Shinjuku-ku, Tokyo, Japan, 169-0073
        • Japan Community Health Care Organization Tokyo Yamate Medical Center
      • Zagreb, Kroatien, 10000
        • University Hospital Center Zagreb
      • Beirut, Libanon, 166830
        • Hotel Dieu de France Hospital
      • Beirut, Libanon, 1100 2807
        • Saint George University Hospital Medical Center
      • Beirut, Libanon, 113-6044
        • Rafik Hariri University Hospital
      • Saida, Libanon
        • Hammoud Hospital University Medical Center
      • Tripoli, Libanon
        • Nini Hospital s.a:l
      • Vilnius, Litauen, LT-08661
        • Vilnius University Hospital Santaros Klinikos
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Chihuahua City, Mexico, 31203
        • Scientia Investigacion Clinica S.C.
      • Chihuahua City, Mexico, 31020
        • Sanatorio Palmore A.C.
      • Chihuahua City, Mexico, 31203
        • Vista Lasser de Chihuahua S.C.
      • Chihuahua City, Mexico, 31283
        • Servicios Hospitalarios de México, S.A. de C.V.
      • Veracruz, Mexico, 91900
        • FAICIC S. de R.L. de C.V.
      • Veracruz, Mexico, 91910
        • Gabinete de Diagnostico COVADONGA
      • Veracruz, Mexico, 91918
        • Alberto Collado Solorzano (Clinica Vision)
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44130
        • Centro de Investigacion Medico Biologica Y Terapia Avanzada S.C.
      • Guadalajara, Jalisco, Mexico, 44600
        • Global Glaucoma Institute
      • Guadalajara, Jalisco, Mexico, 44600
        • Video Endoscopia Americas
      • Guadalajara, Jalisco, Mexico, 44670
        • Comercializadora Winco S.A. de C.V.
    • Veracruz
      • Boca del Rio, Veracruz, Mexico, 94299
        • Cirugia y Gastro de Veracruz S.A. de C.V. (Progastro)
      • Chisinau, Moldova, 2005
        • "Sf. Arhanghel Mihail" Municipal Clinical Hospital, Department of Gastroenterology
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Colorectal Surgery
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Gastroenterology
      • Chisinau, Moldova, MD2025
        • PMSI Republican Clinical Hospital "Timofei Mosneaga", Outpatient Department
      • Bystra, Polen, 43-360
        • Centrum Pulmonologii i Torakochirurgii w Bystrej (DLCO)
      • Karkow, Polen, 31-156
        • Specjalistyczne Gabinety Lekarskie LANDA
      • Krakow, Polen, 30-033
        • Centre De La Vision Centrum Okulistyczne(OCT, Ophthalmoscopy)
      • Krakow, Polen, 30-307
        • Medicina (Endoscopy)
      • Krakow, Polen, 31-153
        • Centrum Medyczne EVITA(Endoscopy)
      • Lodz, Polen, 90-752
        • IP Clinic Sp. z o.o.
      • Lodz, Polen, 90-338
        • Centrum Medyczne "Ksiezy Mlyn" (OCT, Ophtalmoscopy)
      • Lodz, Polen, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatolog i im. M. Kopernika w Lodzi
      • Lodz, Polen, 90-338
        • (Centrum Medyczne Ksiezy Mlyn (OCT and Ophthalmoscopy)
      • Lodz, Polen, 90-644
        • AMICARE Sp. z o.o. sp.k
      • Lodz, Polen, 91-053
        • Centra Medyczne Medyceusz (DLCO)
      • Lodz, Polen, 92-551
        • Salve Health Care Sp. o.o., (PFT and Endoscopy)
      • Nowy Targ, Polen, 34-400
        • Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
      • Oświęcim, Polen, 32-600
        • Medicome Sp. Z O.O
      • Piotrkow Trybunalski, Polen, 97-300
        • Przychodnia Okulistyczna "Oculus" Barbara Cybulska (OCT, Ophtalmoscopy)
      • Piotrkow Trybunalski, Polen, 97-300
        • Samodzielny Szpital Wojewodzki im. Mikolaja Kopernika (Endoscopy)
      • Piotrokow Trybunalski, Polen, 97-300
        • Trialmed CRS
      • Poznan, Polen, 60-529
        • Solurmed Centrum Medyczne
      • Poznan, Polen, 60-538
        • OCU Service Mikolaj Meller Sp.j.(OCT, Ophtalmoscopy)
      • Rzeszów, Polen, 35-326
        • Centrum Medyczne Medyk
      • Rzeszów, Polen, 35-055
        • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie (Ophthalmpscopy)
      • Rzeszów, Polen, 35-241
        • Podkarpackie Centrum Chorob Plue w Rzeszowie (DLCO)
      • Strzegom, Polen, 58-150
        • Strzegomskie Centrum Medyczno - Diagnostyczne Sp. z o.o. (Endoscopy)
      • Swidnica, Polen, 58-100
        • DC-MED
      • Swidnica, Polen, 58-100
        • Centrum Medyczne EZ-MEDICA (OCT, Ophtalmoscopy)
      • Swidnica, Polen, 58-100
        • Szpital "Latawiec" -Poradnia Gruzlicy i Chorob Pluc (PFT)
      • Warsaw, Polen, 00-635
        • Centrum Zdrowia MDM
      • Warsaw, Polen, 00-631
        • Centrum Zdrowia MDM (OCT,opthalmoscopy)
      • Warsaw, Polen, 01-138
        • Instytut Gruzlicy i Chorob Pluc(DLCO)
      • Warsaw, Polen, 02-653
        • Endoterapia PFG (Endoscopy)
      • Warsaw, Polen, 02-653
        • Instytut Oka (OCT, Ophtalmoscopy)
      • Warsaw, Polen, 03-712
        • Specjalistyczne Gabinety Lekarskie Body Clinic
      • Warsaw, Polen, 03-731
        • Centrum Okulistyczne JASKRA (OCT, Ophthalmoscopy)
      • Warsaw, Polen, 04-141
        • Wojskowy lnstytut Medyczny (PFT)
      • Wroclaw, Polen, 60-681
        • EuroMediCare Szpital Specjalistyczny z Przychodniit (Endoscopy)
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen, 60-681
        • NSZOZ Termedica
      • Bucharest, Rumænien, 012015
        • SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
      • Bucharest, Rumænien, 022328
        • Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
    • JUD. CLUJ
      • Cluj-Napoca, JUD. CLUJ, Rumænien, 400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
    • Jud.constanta
      • Constanța, Jud.constanta, Rumænien, 900591
        • Centrul de Diagnostic si Tratament Affidea, Specialitatea Medicina Interna
      • Kemerovo, Rusland, 650066
        • SAIH "Kemerovo Regional Clinical Hospital"
      • Novosibirsk, Rusland, 630005
        • LLC "SibNovoMed"
      • Novosibirsk, Rusland, 630007
        • Gastrocenter
      • Novosibirsk, Rusland, 630007
        • LLC "Novosibirskiy Gastrocentr''
      • Novosibirsk, Rusland, 630084
        • Hospital #12
      • Novosibirsk, Rusland, 630091
        • LLC "Siberian Center for Prevention and Treatment of Myopia Eye"
      • Novosibirsk, Rusland, 630099
        • Joint Stock Company Medical Center "AVICENNA"
      • Omsk, Rusland, 644013
        • BHI of Omsk region "Clinical Oncology Dispensary"
      • Omsk, Rusland, 644024
        • Clinicodiagnostic Center "Ultramed"
      • Omsk, Rusland, 644070
        • Medical center "Intervzglyad"
      • Saint Petersburg, Rusland, 191015
        • FSBI of Higher Education " North-Western Medical University n.a.I.I. Mechnikov '' of MoH RF
      • Saint Petersburg, Rusland, 195067
        • FSBI of Higher Education "North-Western Medical University n.a.I.I. Mechnikov'' of MoH RF
      • Stavropol, Rusland, 355017
        • Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical
    • Stavropol Kray
      • Pyatigorsk, Stavropol Kray, Rusland, 357502
        • LLC "Polyclinic of ultrasonography 4D"
      • Bern, Schweiz, 3010
        • Inselspital Bern
      • Bern, Schweiz, 3012
        • OCT/Ophtalmoscopy: Berner Augenklinik am Lindenhofspital
      • Belgrade, Serbien, 11000
        • Clinical Center Zvezdara
      • Banská Bystrica, Slovakiet, 975 17
        • Fakultna nemocnica s poliklinikou F.D.Roosevelta
      • Bardejov, Slovakiet, 08501
        • ALIAN. s.r.o .. Ambulancia vnutorneho lekarstva
      • Košice, Slovakiet, 040 13
        • ENDOMED, s.r.o. Gastroenterologicka ambulancia
      • Lipany, Slovakiet, 082 71
        • Opthalmology outpatient clinic, MUDr. Michal Popovec, s.r.o.
      • Nitra, Slovakiet, 949 01
        • KM Management spol.s.r.o. Gastroenterologicke a hepatologicke centrum
      • Prešov, Slovakiet, 080 01
        • GASTRO LM s.r.o., Gastroenterologicka ambulancia
      • Prešov, Slovakiet, 080 01
        • Pneumology: PULMO, s.r.o.
      • Las Palmas de Gran Canaria, Spanien, 35010
        • Hospital Universitario de Gran Canaria Dr. Negrín
      • Madrid, Spanien, 28046
        • Hospital Universitario La Paz
    • Ciudad REAL
      • Tomellso, Ciudad REAL, Spanien, 13700
        • Hospital General de Tomelloso
    • Free State
      • Bloemfontein, Free State, Sydafrika, 9301
        • Dr W Simmonds (Gastroenterology Department)
    • Gauteng
      • Benoni, Gauteng, Sydafrika, 1501
        • Worthwhile Clinical Trials
      • Benoni, Gauteng, Sydafrika, 1500
        • Dr K Rahman (OTC and Opthalmoscopy)
      • Benoni, Gauteng, Sydafrika, 1500
        • Lakeview Hospital radiology (Radiology)
      • Benoni, Gauteng, Sydafrika, 1500
        • Worthwhile Clinical trials (PFT)
      • Centurion, Gauteng, Sydafrika, 0157
        • Dr E Meyer & Partners, Centurion Eye Hospital (OTC and Opthalmoscopy)
      • Centurion, Gauteng, Sydafrika, 0157
        • Dr Jorg Reichenberger (Endoscopy)
      • Centurion, Gauteng, Sydafrika, 0157
        • Drs Burger Radiologists Inc (X-ray/CT)
      • Centurion, Gauteng, Sydafrika, 0157
        • Johese Clinical Research, Unitas Hospital
      • Johannesburg, Gauteng, Sydafrika, 2193
        • Wits Clinical Research
      • Kempton Park, Gauteng, Sydafrika, 1619
        • Clinresco Centres (Pty) Ltd
      • Kempton Park, Gauteng, Sydafrika, 1619
        • Burger Radiology (Radiology)
      • Kempton Park, Gauteng, Sydafrika, 1619
        • Dr KJP Lubuya (OCT and Opthalmology)
      • Kempton Park, Gauteng, Sydafrika, 1619
        • Prof O Mwantembe (Endoscopy)
      • Pretoria, Gauteng, Sydafrika, 0002
        • Emmed Research
      • Springs, Gauteng, Sydafrika, 1559
        • Dr K Rahman(OTC and Opthalmoscopy)
      • Sunninghill, Gauteng, Sydafrika, 2196
        • Dr I Moola (Endoscopy)
    • Western Cape
      • Cape Town, Western Cape, Sydafrika, 7405
        • Dr Peter Chapman (PFT + DLCO)
      • Cape Town, Western Cape, Sydafrika, 7441
        • Dr Chris Stander (OCT)
      • Cape Town, Western Cape, Sydafrika, 7441
        • Morton & Partners Radiologists (Radiology)
      • Cape Town, Western Cape, Sydafrika, 7441
        • Spoke Research Inc. Room 109
      • Daegu, Sydkorea, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Sydkorea, 41944
        • Kyungpook National University Hospital
      • Daegu, Sydkorea, 41944
        • Endoscopy Facility in kyungpook National University Hospital
      • Daegu, Sydkorea, 41944
        • OCT Facility In kyungpook National University Hospital
      • Daegu, Sydkorea, 41944
        • PFT Facility in Kyungpook National University Hospital
      • Daejeon, Sydkorea, 34943
        • The Catholic University of Korea, Daejeon ST. Mary's Hospital
      • Incheon, Sydkorea, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Sydkorea, 13496
        • CHA University Bundang CHA Hospital
      • Seoul, Sydkorea, 06273
        • Gangnam Severance Hospital, Yonsei University Health System
      • Seoul, Sydkorea, 06973
        • Chung-Ang University Hospital
      • Seoul, Sydkorea, 02447
        • Kyunghee University Medical Center
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sydkorea, 10326
        • Dongguk University Ilsan Hospital
      • Horažďovice, Tjekkiet, 341 01
        • MUDr. Jaroslava Skalova
      • Hradec Králové, Tjekkiet, 500 12
        • Hepato-gastroenterologie HK, s.r.o.
      • Hradec Králové, Tjekkiet, 500 12
        • VISUS, spol s.r.o.
      • Klatovy, Tjekkiet, 339 01
        • GASTRO JeKa, s.r.o.
      • Klatovy, Tjekkiet, 339 01
        • Klatovska nemocnice a.s.
      • Olomouc, Tjekkiet, 779 00
        • PreventaMed s.r.o.
      • Olomouc, Tjekkiet, 779 00
        • Ocni ordinace Olomouc
      • Olomouc, Tjekkiet, 779 00
        • MUDr. Pavlina Kazinotova s.r.o.
      • Ankara, Tyrkiet (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, Tyrkiet (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Ankara, Tyrkiet (Türkiye), 06800
        • T.C. Saglik Bakanligi Ankara Sehir Hastanesi
      • Antalya, Tyrkiet (Türkiye), 07100
        • Saglik Bilimleri Universitesi Antalya Egitim ve Arastirma Hastanesi
      • Izmir, Tyrkiet (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi Hastanesi
      • Kocaeli, Tyrkiet (Türkiye), 41380
        • Kocaeli University Research and Training Hospital
      • Yenişehir, Tyrkiet (Türkiye), 33343
        • Mersin University Faculty of Medicine
      • Augsburg, Tyskland, 86156
        • Universitaetsklinikum Augsburg
      • Brandenburg an der Havel, Tyskland, 14770
        • Staedtisches Klinikum Brandenburg
      • Frankfurt, Tyskland, 60431
        • Prof. Dr. med. Dr. med. Habil. Jens Buhren, FEBO
      • Frankfurt am Main, Tyskland, 60431
        • Agaplesion Markus Krankenhaus
      • Hamburg, Tyskland, 20251
        • HaFCED e.K. - Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen
      • Jena, Tyskland, 07747
        • Universitaetsklinikum Jena
      • Jena, Tyskland, 07747
        • OCT/Ophtalmoscopy address: Universitaetsklinikum Jena
      • Jena, Tyskland, 07747
        • PFT address: Universitaetsklinikum Jena
      • Kassel, Tyskland, 34121
        • PFT address: Praxis fur Pneumologie und Allergologie
      • Kassel, Tyskland, 34177
        • OCT/Ophtalmoscopy address: Augenarztpraxis Dr. Karola Hassan
      • Kiel, Tyskland, 24105
        • Nordblick Augenklinik
      • Kiel, Tyskland, 24105
        • Universitatsklinikum Schleswig-Holstein- Campus Kiel
      • Nürtingen, Tyskland, 72622
        • Dr. Irina Hasewinkel
      • Nürtingen, Tyskland, 72622
        • Medius Klinik Nuertingen
    • Hassen
      • Kassel, Hassen, Tyskland, 34117
        • Gastroenterologie Opernstraβe
      • Kharkiv, Ukraine, 61124
        • Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council
      • Kharkiv, Ukraine, 61024
        • LLC "EyeQClinic"
      • Kharkiv, Ukraine, 61022
        • Llc "Ldts Skaymed'
      • Kharkiv, Ukraine, 61037
        • Communal Non-commercial Enterprise Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv
      • Kharkiv, Ukraine, 61045
        • Llc "Medical Center Oftalmika"
      • Kharkiv, Ukraine, 61103
        • Municipal Health Care "Kharkiv City Hospital Ambulance and Emergency Medical care
      • Kyiv, Ukraine, 01135
        • Medical Center of Limited Liability Company Harmoniia Krasy
      • Kyiv, Ukraine, 02091
        • Med Center 'Ok!Clinic+' of Comp with limited liability "Int Inst of Clin Research", Unit of Gastro
      • Kyiv, Ukraine, 04210
        • Private Enterprise "Clinic Medicom"
      • Lutsk, Ukraine, 43005
        • CE Volyn Reg Clinical Hospital ofVolyn Reg Council, Surgical (Endocrine and Abdominal Pathology)
      • Vinnytsia, Ukraine, 21000
        • Private Enterprise Diagnostic Center "Mediscan"
      • Vinnytsia, Ukraine, 21009
        • Medical Center of LLC Health Clinic, Medical Clinical Research Center, Unit of Gastroenterology,
      • Vinnytsia, Ukraine, 21018
        • CNE of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Reg
      • Vinnytsia, Ukraine, 21029
        • Scientific and Research Institute of Invalid Rehabilitation (Educational, Scientific and Treatment
      • Budapest, Ungarn, 1136
        • Pannonia Maganorvosi Centrum
      • Budapest, Ungarn, 1033
        • Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft. (abbreviated name: Clinexpert Kft.)
      • Budapest, Ungarn, 1062
        • Ophthalmology procedures: Magyar Honvedseg Egeszsegugyi Kozpont
      • Budapest, Ungarn, 1062
        • Pulmonary procedures: Vasutegeszsegugyi Nonprofit Kozhasznu K ft.
      • Budapest, Ungarn, 1134
        • Ophthalmology, OCT: Medicover Zrt.
      • Budapest, Ungarn, 1139
        • Chest X-ray: XIII. keruleti Egeszsegugyi Szolgalat Kozhasznu Nonprofit Kft.
      • Békéscsaba, Ungarn, 5600
        • Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat es 2. Gasztroenterologia
    • Heves County
      • Gyöngyös, Heves County, Ungarn, 3200
        • Bugat Pal Korhaz, Gasztroenterologia
    • Komárom-Esztergom
      • Tatabánya, Komárom-Esztergom, Ungarn, 2800
        • Szent Borbala Korhaz
      • Tatabánya, Komárom-Esztergom, Ungarn, 2800
        • DLCO and ophthalmology tests: Szent Borbala Korhaz
      • Graz, Østrig, 8036
        • LKH Universitats-Klinikum Graz
      • Innsbruck, Østrig, A-6020
        • Medical University Innsbruck, Internal Medicine Ⅰ
      • Vienna, Østrig, 1090
        • AKH Wien- Universitatsklinik fiir Innere Medizin III
      • Vienna, Østrig, 1090
        • Univ.-Professor Dr. Mehrdad Baghestanian
      • Vienna, Østrig, 1090
        • AKH Wien- Universitatsklinik fur Innere Medizin III

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Beskrivelse

Kvalifikationskriterier, der gælder for alle delundersøgelser:

Inklusionskriterier:

  • Mænd eller kvinder i alderen 18 til 80 år,
  • Evne til at give skriftligt informeret samtykke eller samtykke og være i overensstemmelse med tidsplanen for protokolvurderinger
  • Diagnosticeret med Crohns sygdom (CD) ≥ 3 måneder
  • Har moderat til svær aktiv CD ved screening
  • Påvist utilstrækkelig respons (dvs. primær non-respons), tab af respons på eller intolerance over for ≥ 1 af følgende terapier til behandling af CD:

    1. Orale kortikosteroider (f.eks. prednison eller tilsvarende budesonid)
    2. Immunsuppressiva (f.eks. azathioprin [AZA], 6-mercaptopurin [6-MP] eller methotrexat [MTX])
    3. Tumornekrosefaktor alfa (TNFα) antagonister (f.eks. infliximab, adalimumab, certolizumab pegol eller biosimilars)
    4. Integrinreceptorantagonist (f.eks. vedolizumab)
    5. Interleukin-12/-23-antagonist (f.eks. ustekinumab)
  • Kvinder i den fødedygtige alder skal være ikke-gravide
  • Kvinder i den fødedygtige alder og mænd skal bruge prævention

Ekskluderingskriterier:

  • Anamnese med utilstrækkelig respons (dvs. primær non-respons) på midler fra ≥ 2 klasser af biologiske lægemidler markedsført til behandling af CD (dvs. TNFα-antagonister, interleukin 12/23-antagonist og integrinreceptorantagonist).
  • Har colitis ulcerosa, ubestemt colitis, mikroskopisk colitis, iskæmisk colitis, strålingscolitis, divertikulær sygdomsassocieret colitis, toksisk megacolon eller aktiv infektiøs colitis eller test positiv for Clostridioides difficile-toksin ved screening.
  • Har funktionelt eller postoperativt korttarmssyndrom eller andre associerede komplikationer, der kan kræve operation eller forstyrre effektivitetsvurderinger
  • Havde kirurgisk behandling for intraabdominale abscesser ≤ 8 uger før randomisering eller kirurgisk behandling for perianale abscesser ≤ 4 uger før randomisering.
  • Havde intestinal resektion ≤ 24 uger før randomisering eller andre intraabdominale operationer ≤ 12 uger før randomisering.
  • Har en ileostomi eller en kolostomi.

Inklusionskriterier for delstudie 3:

- Deltagere, der gik ind i den forlængede induktionsperiode for delstudie 1 og delstudie 2, skal have gennemført det forlængede induktions-Uge 6-besøg

Inklusionskriterier for delstudie 4:

- Deltageren skal have gennemført uge 52-besøget i delstudie 3 eller uge 66-besøget i delstudie A

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo
Etrasimod matchende placebotablet tages gennem munden én gang dagligt.
Eksperimentel: Etrasimod dosis A
Dosis A taget gennem munden en gang dagligt.
Andre navne:
  • APD334
Dosis B tages gennem munden en gang dagligt.
Andre navne:
  • APD334
Eksperimentel: Etrasimod dosis B
Dosis A taget gennem munden en gang dagligt.
Andre navne:
  • APD334
Dosis B tages gennem munden en gang dagligt.
Andre navne:
  • APD334

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
Tidsramme: Week 14 of SSA
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Week 14 of SSA
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
Tidsramme: Week 14 of SS1
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD. SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum. Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%. Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed. Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
Week 52 of study

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
Tidsramme: Week 14 of SSA
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Week 14 of SSA
Change From Baseline in SES-CD Score at Week 14: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed. Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CDAI Score at Week 14: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
Tidsramme: 4 hours post-dose on Day 1
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
4 hours post-dose on Day 1
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
Tidsramme: From Week 2 to Week 14
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
From Week 2 to Week 14
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in ALC at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
Change From Baseline in CRP at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
Tidsramme: Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
Tidsramme: Week 14 of SS1
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
Tidsramme: Week 14 of SS1
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. MI method was used; percentage was calculated based on average response rate from MI datasets.
Week 14 of SS1
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was CDAI score <150. CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum. Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers. Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%. Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed. Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to FMD date.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
Tidsramme: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline). CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10. Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed. Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables. Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease. Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD. SES-CD comprised of 4 components assessed for 5 bowel segments. Each component score ranged from 0-3, higher scores indicated more severe condition. Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease. Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
Week 52 of study
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 20, 28, 36, 44, 52
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44, 52
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150. CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms. Each module ranged from 0 to 16, where higher scores indicated more severe disease. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD. Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life. The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality. The 8 domains are combined to form 2 component scores MCS and PCS. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 28 and 52
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue). SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 28 and 52
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Week 52 of study
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
Tidsramme: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
Tidsramme: Baseline, study Weeks 20, 28, 36, 44 and 52
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
Baseline, study Weeks 20, 28, 36, 44 and 52
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
Tidsramme: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Tidsramme: From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization. Clinical remission by PRO2 was defined as PRO2 score <8. Normalization of FCP was defined as FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
Tidsramme: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
Tidsramme: From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization. Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score. Clinical remission by PRO2: PRO2 score <8. Normalization of FCP: FCP <=150 milligrams per kilogram. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain. Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
Tidsramme: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
Tidsramme: Baseline and Week 52 of study
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum. Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers. Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%. Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%. Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed. Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease. SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
Baseline and Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD. SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease. Clinical remission by PRO2: PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
Tidsramme: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
Tidsramme: Week 52 of study
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1. SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition. Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease. Clinical remission by PRO2 was defined as PRO2 score <8. PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. Stool frequency was number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor. PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
Week 52 of study
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
Tidsramme: Baseline, Weeks 52, and 104 of SS4
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: >500 (milliseconds [msec]); change from SS4 baseline >30 msec and change from SS4 baseline >60 msec. QT interval corrected using Fridericia's formula (QTcF) (msec): >=450 (male) or >=470 (female) msec; change from SS4 baseline >30 msec; change from SS4 baseline >60 msec. PR interval (msec): >230 msec. Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 52, and 104 of SS4
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs of Special Interest: SS3
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular [AV] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment. SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant. AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment. Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With TEAEs of Special Interest: SS4
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies. Number of participants with any TEAEs of special interest were reported in this outcome measure.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
Tidsramme: From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN); Ery. Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN), Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN); Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase. Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20. Number of participants with any laboratory abnormality meeting specified criteria is included.
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
Tidsramme: Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury [mmHg]): low: <=90 mmHg and high: >150 mmHg. Diastolic blood pressure (mmHg): low: <=50 mmHg and high: >90 mmHg. Heart rate (beats per minute [bpm]): low: <40 bpm, <50 bpm and high: >100 bpm. Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure. SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tidsramme: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was considered as CDAI score <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tidsramme: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical Response was defined as having clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI <150. CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10. Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
Tidsramme: Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
Clinical remission was defined as PRO2 score <8. The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI. The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days. The stool frequency was defined as number of liquid or soft stools each day for 7 days. Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor. The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. januar 2020

Primær færdiggørelse (Faktiske)

23. april 2025

Studieafslutning (Faktiske)

9. juni 2025

Datoer for studieregistrering

Først indsendt

20. november 2019

Først indsendt, der opfyldte QC-kriterier

20. november 2019

Først opslået (Faktiske)

21. november 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • APD334-202
  • C5041006 (Anden identifikator: Alias Study Number)
  • 2024-513569-38-00 (Registry Identifier: CTIS (EU))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer vil give adgang til individuelle afidentificerede deltagerdata og relaterede undersøgelsesdokumenter (f.eks. protokol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) efter anmodning fra kvalificerede forskere og underlagt visse kriterier, betingelser og undtagelser. Yderligere detaljer om Pfizers datadelingskriterier og proces for at anmode om adgang kan findes på: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner